Sintx Technologies, Inc. SINT
Nasdaq · XNAS · stock · Surgical & Medical Instruments & Apparatus
Chart by TradingView
2/9
Piotroski F — financial health
-105.96
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $1.0M | -$10.4M | $461,000 | -$8.8M | $2.9M |
| 2024 | $2.9M | -$11.0M | $2.1M | -$9.3M | $3.9M |
| 2023 | $2.6M | -$8.3M | $1.8M | -$14.6M | $8.8M |
| 2022 | $1.6M | -$12.0M | $1.3M | -$11.7M | $5.7M |
| 2021 | $606,000 | -$9.3M | $157,000 | -$13.9M | $17.2M |
| 2020 | $594,000 | -$7.0M | $119,000 | -$9.5M | $25.8M |
Why these scores methodology →
Piotroski F-score: 2/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -105.96 (distress)
- Working capital / assets 0.202
- Retained earnings / assets -30.728
- EBIT / assets -1.128
- Equity / liabilities 0.445
Source: SEC EDGAR filings · CIK 0001269026 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.